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The capacity ofvarious cell typesto infiltrate inflammatory sites suggests the exis-
tence of specific chemotactic cytokines for each cell type. Snyderman et al. (1) first
described that leukocytes from human peripheral blood when stimulated in vitro
with a specific antigen (purified protein derivative [PPD]) or a nonspecific mitogen
(PHA) produced a soluble factor that was chemotactic for homologous monocytes
(2). The production of this lymphokine proved to be a sensitive in vitro correlate
of delayed hypersensitivity (1). We have previously reported the identification,
purification, and cDNA cloning ofa novel neutrophil chemotactic factor(NCF) pro-
duced by LPS-stimulated human monocytes (3-5). In the course of identifying NCF,
we detected in the same LPS-stimulated human monocyte-conditioned media a
chemotactic activity for monocytes that was distinct in molecular weight from NCF.
Since the level of monocyte chemotactic factor (MCF) in these conditioned media
was at least 10 timesless than that ofNCF, we used conditioned media from a human
myelomonocytic cell line (THP-1) as a source of MCF The identical conditioned
media were previously used for the purification of human IL-1/3 (6). We now report
the purification of human MCF produced by THP-1 cells to homogeneity and de-
scribe the potent monocyte activating factor (MAF) activity of this MCE
Materials and Methods
Chromatography ProceduresforthePurification ofMCF.
￿
(a) For Heparin Sepharose chromatog-
raphy, the 200-ml DEAE Sephacel breakthrough fraction was applied to 50 ml Heparin
Sepharose (Pharmacia Fine Chemicals, Uppsala, Sweden), that had been equilibrated with
0.05 M Tris-HCl, pH 8.0, with 0.2 M NaCl. After washing the column extensively, MCF
was eluted with 50 mM Tris HCI, pH 8.0, with 0.75 M NaCI. (b) For gel filtration, the 4-ml
concentrate from Heparin Sepharose was loaded onto a 2.6 x 90-cm column of Sephacryl
S-200 (Pharmacia Fine Chemicals) equilibrated with D-PBS at 4°C. The flow rate was ad-
justed to 15 ml/h and 8-ml fractions were collected. (c) For cation HPLC, fractions corre-
sponding 10-25 kD in gel filtration were concentrated and dialyzed against 0.02 MOPS, pH
6.5, and applied to a 7.5 x 150-mm CM-3SW column (Toyo Soda, Tokyo, Japan) equipped
to an HPLC system (model 2150; LKB Instruments, Inc., Sweden) that had been equilibrated
with the same buffer. The starting buffer was 0.02 M MOPS, pH 6.5, and the limiting buffer
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was 0.02 M MOPS, pH 6.5, with 0.5 M NaCl. The flow rate was 1.0 ml/min and 2.0-ml
fractions were collected. MCF was eluted at ^0.25 M NaCl. (d) For reverse phase chroma-
tography, the active fractions from CM-HPLC were directly applied to a 4.6 x 750-mm
TMS-250 Ultropac column (10 gm; Toyo Soda). The starting solvent was waterwith 0.01%
trifluoroaceticacid (TFA) (Pierce Chemical Co., Rockford, IL), and the limiting solvent was
60% acetonitrile (J. T. Baker Chemical Co., Phillipsburg, NJ) with 0.01% TFA.
Monocyte Chemotactic Assay.
￿
Monocyte chemotactic activity was measured in a multiwell
Boyden chemotaxischamber (Neuro Probe Inc., CabinJohn, MD), as reported (1, 2). MCF
was serially diluted in RPMI 1640 medium with 0.5 % BSA and added to the lower chamber.
Monocyte-enriched leukocytes were obtained from the National Institutes ofHealth Clinical
Center Transfusion Medical Department (Bethesda, MD) and further separated on Ficoll-
Hypaque. The purity of monocytes in this preparation was 30-50% and no neutrophil con-
tamination was detected after staining with Giemsa solution. These mononuclear cells at
106/ml RPMI 1640 medium with 0.5% BSA were added into upper chambers. Two chambers
were separated by an 8-Am pore size polyvinyl pyrolidone-free polycarbonate filter (Nucleo-
pore, Pleasanton, CA). The chamber was incubated at 37°C for 90 min. The migrated cells
that adhered to the lower surface of the membrane were fixed with methanol and stained
with Giemsa solution. The migrated cells consisted of >95% monocytes by microscopic
analysis.
Tumor Growth Inhibition Assay.
￿
105 monocyte-enriched cells from leukapheresis (supplied
by the NIH Clinical Center Transfusion Medical Department) in 100 p.l RPMI 1640 medium
with 5 % FCS (Hyclone Laboratories, Logan, UT) were plated in 96-microwell culture plates.
After incubating cells for 1 h at 370C, nonadherent cells were removed by aspiration and
washed twice with the same medium warmed to 37°C. The adhered monocytes were >90%
pure by nonspecific esterase staining. Human tumor cell lines, all of which were obtained
from the American Type Culture Collection (Rockville, MD), were detached by EDTA/trypsin
treatment, washed twice with the same RPMI medium, and 104 cells in 100 p,l RPMI
medium were added into monocyte-containing wells. Serially diluted purified MCF was then
added and cells were cultured for 72 h at 37'C in a C02 incubator. The cells were incubated
for the final 6 h with 0.5 /ACi [3H]TdR, where incorporation of thymidine into cells was
measured.
Results and Discussion
21 liters of conditioned media from THP-1 cells was cultured at 2 x 106/ml for 2 d
in spinner culture flasks in the presence of 1 wg/ml LPS, 50 lLg/ml silica, and 2 mM
hydroxyurea, as previouslydescribed (6). The conditioned media were concentrated,
dialyzed against 10 mM sodium phosphate buffer (NaPB), pH 7 .5, by a hollow fiber
system, and applied to a DEAE Sephacel column that was equilibrated with the
same buffer. Monocyte chemotactic activity in the breakthrough fraction was fur-
ther purified by sequential chromatography using heparin Sepharose, Sephacryl S-200
gel filtration, CM-cation exchange HPLC, and C-1 reverse phase HPLC. Fig. 1 a
shows the results of the final chromatography on reverse phase HPLC. There was
complete identity between one ofthe major protein absorbance peaks and monocyte
chemotactic activity. The material yielded only one band by silver staining on
SDS-PAGE analysis with an estimated molecular weight of 15,000, as shown in Fig.
1 b. The overall recovery of MCF activity was 7.3% and 2 hg of pure MCF was
obtained from 21 liters of conditioned media. Since no significant amount ofcleaved
amino acid could be detected at the NH2 terminal by Edman degradation sequence
analysis on a gas phase sequencer, the purified material was cleaved by cyanogen
bromide (CNBr) and sequenced again. The partial amino acid sequence of one of
the CNBr-cleaved peptides was NH2-(Met)-Asp-His-Leu-Asp-Lys-GlnThr-Gln-
X-Pro-Lys-Thr. The computer-assisted comparisonofthis peptide sequence with otherMATSUSHIMA ET AL .
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FIGURE 1
￿
(a) Reverse phase HPLC of human NICE After evaporation of samples from each
fraction, MCF activity was measured . (b) SDS-PAGE analysis of purified human MCE 15%
acrylamide gel with stacking gel was used . After electrophoresis, the gel was stained with silver
staining. Low molecular weight marker protein mixture (Pharmacia Fine Chemicals) was used
as standard.
known polypeptides did not show any significant homology/similarity. The purified
MCF was free from endotoxin (<0.1 ng/ml in fraction 45 and 46 from reverse phase
HPLC as measured by Limulus amebocyte lysate assay) and gave a halfmaximal
chemotactic activity of0.46 ng/ml forhumanunstimulated monocytes usingamulti-
well Boyden chamber system . MCF had a specific of2.1 x 106 U/mg, defining 1 U
as the reciprocal of the dilution at which halfmaximal chemotactic activity was ob-
tained . MCF failed to show any significant chemotactic activity at 0.01 ng/ml to
100 ng/ml forhuman peripheral blood restingT lymphocytes or fornormal neutro-
phils (data not shown) .
To establish other possible effects ofMCF on the function ofhuman monocytes,
we examined whetherthis factor stimulated human monocytes to be growth inhibi-
tory for tumor cells . As shown in Fig . 2, purifiedMCF in a dose-dependentmanner
augmented the growth inhibitory effects ofhumanmonocyteson several human tumor
cell lines, including a melanoma cell line A375 C-5 (IL-1 resistant), A375 C-6 (IL-1
sensitive) (7-9), amammary tumor cell line MCF7, acolon carcinoma cell lineHT 29,
a rhabdomyosarcoma cell line HTB 82, and a leiomyosarcoma cell line HTB 88 .
No significant inhibition oftumor cell growth was observed byMCF-activated mono-
cytes on human glioma cell lines HTB 16, U373, andHTB 14 ; and human bladder
carcinoma cell lines HTB 3 and HTB 4. The effective dose yielding half-maximal
MAF activity was similar to that for chemotactic activity. Polymyxin B at 10 Fig/ml
did not block the activation of monocytes by MCF . We did not observe any direct
growth inhibitory activity of this factor on these tumor cells. Time course experi-
ments showed the growth inhibitory activity of MCFtreated monocytes to begin
at 2 d andbecome maximalat 3 d ofincubation (datanot shown) . Prolonged culture
ofA375 cells with monocytes in the presence ofMCF led to lysis of only tumor
cells at 4-5 d as determined by lightmicroscopy. Conditioned mediafrom MCFstim-1488
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￿
Augmentation oftu-
morgrowth inhibitory activity
ofhumanmonocytesby purified
MCF. [3H]TdR incorporation
by monocytes was <300 cpm.
ulated human monocytes failed to inhibit the growth ofA375 cells and antibodies
to IL-1a, IL-la, TNFa, and IL-6 didnot block thecapacity ofMCFtreated mono-
cytes to inhibit thegrowth ofA375cells, suggesting that these cytokinesdo notmediate
either monocyte activation by MCForthecytostatic/cytocidal effect ofMCFstimulated
monocytes on tumor cells. MCF also induced morphological changes in monocytes
such as irregularity ofshape and increased agglutination but not spreading by sev-
eral hours to 3 d (data not shown).
We have described thepurification ofanovel MCFwith considerable MAF activ-
ity from the conditioned mediaofahuman myelomonocytic cell line. Although the
myelomonocytic cellline source ofthis factor was surprisingand suggested that MCF
may be an autostimulatory factor, a similar phenomenon has been observed with
othermonocyte/macrophageproducts, such as IL-1 (9), TNFa (10), and IFN-(3 (11).
There appear to be distinct chemotactic factors for each inflammatory cell type.
We have rencently reported the purification and cDNA cloning of a NCF derived
from LPS-stimulated human monocytes (4, 5). In addition, our recent purification
ofTlymphocytechemotactic factor from PHA-stimulated humanPBMC-conditioned
media showed it to be identical to NCF (12). It has also been reported that IL-5
(T cell-replacing factor) is chemotactic for mouse eosinophils (13) and that NCF
is not chemotactic for eosinophils (14). Therefore, it is clear that there are several
leukocyte-derived chemotactic polypeptides that attract distinct cell populations in
vitro. The target cell specificity ofthese factors could be based on the exclusive ex-
pression of the receptor for these factors on target cells. The in vivo effect on cell
migration ofthese chemotactic polypeptides remains to be established. The bifunc-
tional capability of MCF (chemotactic activity and monocyte activating activity)
suggests that MCF may have local and perhaps systemic in vivo inhibitory effectsMATSUSHIMA ET AL.
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on tumor growth. The effects ofMCF on other functions of monocytes and the growth
and differentiation of immature myeloid cells and leukemic cells also merit study.
The cDNA cloning ofthis novel MCF/MAF is in progress to permit further structure-
function studies and to produce recombinant MCF molecules. The identification
of MCFproducing cells in inflammatory site, delayed-type hypersensitivity site, and
certain diseases will be examined when specific antibodies to MCF and cDNA probe
become available.
Summary
A novel basic heparin-binding monocyte chemotactic factor (MCF) was purified
to homogeneity from the conditioned media ofhuman myelomonocytic cell line THP-1
based on its in vitro monocyte chemotactic activity. The purified MCF was homoge-
nous and estimated to be 15 kD on SDS-PAGE. Purified MCF stimulated normal
human monocytes to be growth inhibitoryin vitro at 2-3 d for several human tumor
cell lines. This represents the first report of the identification and purification of
a chemoattractant cytokine that also activates monocytes but is distinct from inter-
ferons and other known cytokines.
We are grateful to Mrs. Kathleen Bengali for excellent technical assistance and Drs. Dan
Longo and Naofumi Mukaida for reviewing the manuscript.
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